Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TTPA | P49638 | 2/20 | 0.62 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27417859 | 0.93 | LMNA (0.73) | LMNAMAPTMEN1KMT2ATTPA | |
| SCHEMBL27417872 | 0.93 | LMNA (0.73) | LMNAMAPTMEN1KMT2ATTPA | |
| SCHEMBL27418209 | 0.92 | LMNA (0.62) | LMNAMAPTMEN1KMT2ATTPA | |
| SCHEMBL27418223 | 0.92 | LMNA (0.62) | LMNAMAPTMEN1KMT2ATTPA | |
| SCHEMBL13052447 | 0.88 | LMNA (0.65) | LMNAMAPTMEN1KMT2ATTPA | |
| SCHEMBL21923002 | 0.85 | LMNA (0.85) | LMNAMAPTMEN1KMT2ATTPA | |
| SCHEMBL11036634 | 0.80 | LMNA (0.83) | LMNAMAPTMEN1KMT2ATTPA | |
| Alpha-Tocopherol SCHEMBL27829065 | 0.78 | LMNA (0.91) | LMNAMAPTMEN1KMT2ATTPA | |
| Alpha-Tocopherol SCHEMBL28072150 | 0.78 | LMNA (0.95) | LMNAMAPTMEN1KMT2ATTPA | |
| Alpha-Tocopherol SCHEMBL3059188 | 0.77 | LMNA (1.00) | LMNAMAPTMEN1KMT2ATTPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228454-A1 | RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASE IN TWO-PHASE SYSTEM | DSM IP ASSETS B.V. (NL) | 2024-07-11 | — | — | US | disclosed |
| US-20240228454-A1 | RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASE IN TWO-PHASE SYSTEM | DSM IP ASSETS B.V. (NL) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228454-A1 | RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASE IN TWO-PHASE SYSTEM | TTPA, SQLE, VKORC1 | LMNA 770/4885MAPT 4362/4885MEN1 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.